Faron Pharmaceuticals Oy (HEL:FARON)
Finland · Delayed Price · Currency is EUR | Market Cap | 77.68M -63.5% |
| Revenue (ttm) | n/a |
| Net Income | -30.95M |
| EPS | -0.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,068,917 |
| Average Volume | 1,719,079 |
| Open | 0.5490 |
| Previous Close | 0.5530 |
| Day's Range | 0.5400 - 0.6260 |
| 52-Week Range | 0.4915 - 3.3450 |
| Beta | 1.35 |
| RSI | 21.51 |
| Earnings Date | Mar 4, 2026 |
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company... [Read more]
Financial Performance
Financial StatementsNews
Faron Pharmaceuticals To Earn Spotlight At IUIS 2025 With Its Bexmarilimab Data
At IUIS 2025, Dr. Mika Kontro, MD, PhD, will deliver a presentation titled "Efficacy of Macrophage Checkpoint Clever-1 Inhibition with bexmarilimab plus Azacitidine in Myelodysplastic Syndrome: Result...